Radiological imaging features of glioblastoma with oligodendroglioma component: a comparison with conventional glioblastoma

Masafumi Kanoto¹, Kazukuni Kirii¹, Yuuki Toyoguchi¹, Masashi Nishihara², Keita Sakurai³, Kazuhiro Murayama⁴, Tomoyuki Noguchi⁵, Kenichiro Matsuda⁶, Kaori Sakurada⁶, Yukihiko Sonoda⁶ and Takaaki Hosoya¹

Abstract

Background: Glioblastoma with oligodendroglioma component (GBMO) is a subtype of conventional glioblastoma (cGBM), which is categorized as WHO grade IV. GBMO can be histopathologically distinguished from cGBM and the prognosis of GBMO is better than that of cGBM. However, no systematic review of GBMO imaging findings has been published to date.

Purpose: To clarify the radiological imaging features of GBMO compared with those of cGBM.

Material and Methods: The participants were 15 patients with GBMO and 32 patients with cGBM as a control group, all of whom were histopathologically diagnosed. A radiologist retrospectively reviewed the imaging findings of both computed tomography (CT) and magnetic resonance imaging (MRI) for density, signal intensity, contrast medium enhancement (CE), cortical swelling, and cortical swelling without CE. We statistically analyzed the imaging findings by Chi-squared test.

Results: Cortical swelling without CE in GBMO was significantly greater than that in cGBM (P = 0.004). Non-CE and heterogeneous solid enhancement were observed significantly more often in GBMO (P = 0.004). No other findings were significant.

Conclusion: There was significant difference in the findings of the CE, which exhibited solid heterogeneous enhancement in GBMO. Cortical swelling without CE can be considered significantly characteristic of GBMO.

Keywords
Glioblastoma, oligodendroglioma, glioblastoma with oligodendroglioma component, computed tomography (CT), magnetic resonance imaging (MRI)

Date received: 29 July 2016; accepted: 28 September 2016

Introduction

Glioblastoma (GBM) is categorized as World Health Organization (WHO) grade IV and is one of the most malignant of all brain tumors. GBM is the most common brain tumor, accounting for approximately 12–15% of all intracranial tumors and 60–75% of astrocytic tumors (1). As GBM often exhibits broad infiltrative spread in the brain parenchyma and various fibers, it is very difficult to resect and treat entirely, even

¹Department of Diagnostic Radiology, Yamagata University Faculty of Medicine, Yamagata, Japan
²Department of Radiology, Saga University Faculty of Medicine, Saga, Japan
³Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
⁴Department of Radiology, Fujita Health University, Fuijita, Japan
⁵Department of Radiology, National Center for Global Health and Medicine, Japan
⁶Department of Neurosurgery, Yamagata University Faculty of Medicine, Yamagata, Japan

Corresponding author:
Masafumi Kanoto, Department of Diagnostic Radiology, Yamagata University Faculty of Medicine, Iida-Nishi 2-2-2, Yamagata 990-9585, Japan.
Email: mkanoto@med.id.yamagata-u.ac.jp
when irradiation and chemotherapy are also included. GBM also frequently recurs and causes cerebrospinal disseminations in the early phase after initial therapy (2,3). Generally speaking, the prognosis is extremely poor, with a one-year survival rate of less than 20% (4).

Glioblastoma with oligodendroglioma component (GBMO) is a subtype of conventional glioblastoma (cGBM), which is categorized as grade IV in the WHO classification 2007 (1). GBMO is histopathologically diagnosed as anaplastic oligoastrocytoma with necrosis and is presumed to develop from mixed low-grade glioma, which may result in the malignant transformation (5). GBMO has the pathological features of both glioblastoma and oligodendroglioma and also contains foci that resemble oligodendroglioma (1). These areas vary in size and frequency (1). GBMO can be histopathologically distinguished from cGBM.

GBMO comprises approximately 4–20% of cGBM (5,6). GBMO frequently involves the loss of heterozygosity (LOH) 1p/19q, which is a good prognostic factor in oligodendroglioma, IDH1 mutation, etc. (7–9). Therefore, the prognosis of GBMO is better than that of cGBM (5,9,10). Although GBMO is discouraged in WHO classification 2016, this classification does state the existence of the GBM including the oligodendroglioma component (11). Some of these cases may be characteristic of IDH1 mutation (11). In terms of image analysis, it has been reported that quantitative susceptibility weighted imaging (SWI) is able to depict minute calcification in tumors. Thus, quantitative SWI may be useful in distinguishing GBMO from cGBM (12).

### Oligodendroglioma (WHO grade IV)

Oligodendroglioma (WHO grade IV) exhibits more characteristic calcification and cortical swelling compared with diffuse astrocytoma (13). We

---

**Table 1. Features of each patient group.**

|                        | GBMO (n = 15) | cGBM (n = 32) | P value |
|------------------------|---------------|---------------|---------|
| Mean age               | 58.7 ± 18.1   | 63.6 ± 9.4    | 0.33*   |
| Gender (M : F)         | 12 : 3        | 13 : 19       | 0.008†  |
| Occurrence site        |               |               |         |
| Frontal                | Frontal 3     | Frontal 11    |         |
| Temporal               | Temporal 3    | Temporal 12   |         |
| Parietal               | Parietal 2    | Parietal 5    |         |
| Basal ganglia          | Hypothalamus 1| Corpus callosum 2 |         |
| Hypothalamus           | Insula 1      | Occipital 1   |         |
| Insula                 | Cerebellum 2  | Medulla oblongata 1 |         |
| Cerebellum             | Corpus callosum 2 |         |         |
| MIB-1 index (%)        | 43.1 ± 19.3   | 14.1 ± 16.3   | 0.001*  |

*Student’s t-test, *P* < 0.05 is considered significant.
†Chi-squared test, *P* < 0.05 is considered significant.
hypothesize that computed tomography (CT) and magnetic resonance imaging (MRI) will reveal that GBMO has features of both cGBM and oligodendroglioma. We also found cortical swelling without contrast medium enhancement (CE) in GBMO. No systematic review of GBMO imaging findings using conventional imaging techniques has been published to date. The purpose of this study was to clarify the radiological imaging features of GBMO compared with those of cGBM.

Material and Methods

Participants

The protocol was approved by each institution’s ethical committee. All human and animal studies were approved by the ethical committee and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.

We collected CT/MRI images and medical records of GBMO cases from four institutes (including our own) because of the rarity of this condition. Nineteen patients with GBMO were included. Four patients were excluded since the images had been discarded because the medical records and images of the patients who had not been admitted to hospitals for five years are not preserved in our country. The participants were thus 15 patients with GBMO (male:female ratio = 12:3; mean age, 58.7 ± 18.1 years; period, December 2006 to July 2014) in three institutes and 32 patients with cGBM as a control group (male:female ratio = 13:19; mean age, 63.6 ± 9.4 years; period, January 2010 to July 2014) in one institute. The number of normal controls was approximately twice the number of GBMO cases. All tumors were resected or biopsied by a neurosurgeon and were histopathologically diagnosed by each institute’s pathologist.

Image analysis

A diagnostic radiologist (KK) with 10 years of experience retrospectively and blindly reviewed the imaging findings of both CT and MRI for GBMO and cGBM. KK evaluated density (high/low), hemorrhage, calcification on CT, signal intensity (high/iso/low) on each MRI sequence, and CE in MRI. If the tumor had mixed density/intensity, KK recorded the dominant findings. KK evaluated both cortical swelling and cortical swelling without CE, which is characteristic of oligodendroglial tumors, in the image analysis. However, CT was not performed in one patient with GBMO. “Cortical swelling” was defined as swelling of the cortex due to tumor involvement with/without CE and “cortical swelling without CE” as the existence of a

Fig. 2. Overall survival rate in the two kinds of tumors. The overall survival rate of GBMO is superior to that of cGBMO. However, there is no statistical significance between the two tumors (by log-rank test).
portion without CE in the swollen cortex due to tumor involvement in the T2-weighted (T2W) image and/or the T1-weighted (T1W) image and/or the FLAIR image (Fig. 1).

A neuroradiologist (MK) with 13 years of experience retrospectively examined the occurrence site of the tumor, survival period, the existence of IDH1 mutation, and MIB-1 index using the available medical records.

### Statistical analysis

The overall survival rate for GBMO and cGBM was calculated and evaluated by log-rank test using the available data. The MIB-1 index between GBMO and cGBM was also evaluated by Student’s t-test using the available data. CT and MRI findings of GBMO and cGBM were analyzed by Chi-squared test. These data were statistically calculated using the Statistical Package for the Social Sciences, Version 22.0 (SPSS Inc., Chicago, IL, USA). A P value < 0.05 was considered significant.

### Results

The features of each patient group are summarized in Table 1. GBMO is more likely to occur in men. The MIB-1 index of GBMO is significantly higher than that of cGBM. IDH1 mutation was checked in seven of the cases and two of these cases were IDH1 mutation positive. IDH1 mutation was not checked for the remaining cases. The overall survival rate for GBMO was higher than that for cGBM. The mean follow-up period for GBMO was 22.1 months (14 patients’ follow-up data available) and that for cGBM 20.0 months (26 patients’ follow-up data available). There was no statistical significance between the two kinds of tumors in the overall survival rate (P = 0.549, by log-rank test) (Fig. 2). There were no significant different findings on CT in terms of density, calcification, and hemorrhage between GBMO and cGBM. MRI signal intensity in T1W imaging/T2W imaging/diffusion-weighted imaging (DWI)/apparent diffusion coefficient (ADC) sequences was not

### Table 2. Image findings of GBMOs compared with cGBM.

|       | GBMO (n = 15) | cGBM (n = 32) | P value |
|-------|---------------|---------------|---------|
| CT    |               |               |         |
| Density |               |               |         |
| High   | 8/14          | 17/32         | 0.801   |
| Low    | 6/14          | 15/32         |         |
| Calcification | 3/14          | 4/32          | 0.438   |
| Hemorrhage | 2/14          | 3/32          | 0.622   |
| MRI   |               |               |         |
| T1W images |               |               |         |
| High   | 0/15          | 0/32          | —*      |
| Low    | 15/15         | 32/32         |         |
| T2W images |               |               |         |
| High   | 15/15         | 32/32         | —*      |
| Low    | 0/15          | 0/32          |         |
| DWI   |               |               |         |
| High   | 15/15         | 31/32         | 0.489   |
| Low    | 0/15          | 1/32          |         |
| ADC   |               |               |         |
| High   | 11/15         | 4/32          | 0.228   |
| Low    | 4/15          | 28/32         |         |
| Cortical swelling | 13/15         | 27/32         | 0.837   |
| Cortical swelling without CE | 12/15         | 11/32         | 0.004†  |
| CE    |               |               |         |
| No    | 1/15          | 0/25          | 0.004†  |
| Homo  | 0/15          | 0/25          |         |
| Hetero| 9/15          | 6/25          |         |
| Hetero with ring-like CE | 5/15          | 26/32         |         |

*P value cannot be calculated.
†Chi-square test, P < 0.05 is considered significant.

Fig. 3. A 70-year-old man with GBMO. CT and FLAIR shows a high-density tumor-like cortex with edema in the right temporal lobe (a, b). T1W images with CE reveal solid heterogeneous enhancement (→) and cortical swelling without CE (▽) (c).
significant either. Cortical swelling was not significantly different between the two tumor types.

There was, however, significant difference in the findings of CE ($P = 0.004$). Nine patients with GBMO had heterogeneous solid enhancement and one patient had no enhancement. In contrast, all patients with cGBM had heterogeneous ring-like enhancement. In particular, 12 patients with GBMO had cortical swelling without CE, including no enhancement in one patient, which was significant ($P = 0.004$) (Table 2).

**Discussion**

We revealed that GBMO has significant difference in the findings of CE. Solid heterogeneous enhancement and cortical swelling without CE, in particular, is significantly characteristic of GBMO compared to the findings of cGBM. There is no significant difference in the other findings between the two kinds of tumors.

Oligodendrogliomas are likely to involve the cerebral cortex histopathologically (14). Thus, cortical swelling was frequently seen in our image analysis as well. However, cortical swelling alone is not a significant finding because it is frequently seen in cGBM. In particular, cortical swelling without CE is significantly seen in 80% of GBMOs and in 34% of cGBMs (Table 2). Cortical swelling without CE was defined as the part of the cortical swelling area on T2W images and/or T1W images and/or FLAIR images without CE area in the swollen cortex. Cortical swelling without CE resembles cortical involvement in oligodendroglioma and oligoastrocytoma. It is a specific finding of GBMO and it may reflect the oligodendroglioma component in glioblastoma in this tumor (Table 2, Figs. 3–5). It is difficult to distinguish between the two kinds of tumors using other findings besides CE and cortical swelling without CE.

It is important to distinguish GBMO from cGBM in pretherapeutical image analysis because of the differing prognoses (5,9,10). We hypothesize that GBMO has features of both cGBM and oligodendroglioma in CT and MRI. Calcification, which is characteristic of oligodendroglioma, does not enable us to distinguish GBMO from cGBM. GBMO could not be separated from cGBM using CT. SWI may enable us to observe
small calcifications or microcalcifications (12). However, SWI was unavailable in many of our patients with GBMO and cGBM. Oligodendrogliomas may have mild and/or marked solid enhancement or no enhancement at all (15,16). On the other hand, cGBM has characteristic marked heterogeneous ring-like enhancement. All of our patients with cGBMs had heterogeneous ring-like enhancement. Nine patients with GBMO showed heterogeneous solid enhancement, which differed from both heterogeneous ring-like enhancement and no enhancement (Table 2, Figs. 3 and 4). One report states that the microvascular density of GBMO is lower than that of cGBM and anaplastic astrocytoma, categorized as WHO grade III (17). This may result in the significant difference between the two kinds of tumors in terms of CE.

Conventional glioblastoma is the most malignant brain tumor of all astrocytic tumors, categorized as WHO grade IV. GBMO is a subtype of cGBM, which is also categorized as WHO grade IV (1,5,19). GBMO has the pathological features of both glioblastoma and oligodendroglioma and also contains foci that resemble oligodendroglioma. These areas vary in size and frequency (1). Thus, GBMO can be histopathologically distinguished from cGBM and GBMO may differ from cGBM in our image analysis. It is of clinical importance that the prognosis of GBMO is better than that of cGBM because GBMO frequently involves the loss of heterozygosity (LOH) 1p/19q, which is a good prognostic factor in oligodendroglioma, IDH1 mutation, etc. (7–9,20,21). Several studies report that

**Fig. 5.** A 27-year-old man with GBMO. The tumor is in the left temporal lobe. Both cortical swelling without CE (a–c, V) and heterogeneous ring-like enhancement (d, →) is seen.
GBMO has a significantly better prognosis than cGBM (5,9,10,22). Our patients with GBMO had a better prognosis (approximately 60%) compared to those with cGBM, although there was no statistical significance (Fig. 2). The prognosis of GBMO may be influenced by the oligodendroglial component in the tumor. A high MIB-1 index indicates high proliferation and a bad prognostic factor (23). However, the MIB-1 of GBMO was higher than that of cGBM. This discrepancy needs further study through the evaluation of more GBMO cases.

This study contains several limitations. GBMO in the WHO classification 2007 is discouraged in the WHO classification 2016 (11). However, the WHO classification 2016 suggests that GBMO may consist of IDH-wild type glioblastoma, including, in particular, the small cell variant, given the morphological overlap with oligodendroglial cells, IDH-mutant glioblastoma, or IDH-mutant and 1p/19q codeleted anaplastic oligodendroglioma (11). IDH mutation was not checked in all cases because many of the patients were treated before the importance of genomic study had become widespread. We dealt with a small number of patients with GBMO because it is relatively rare. In image analysis, it may be difficult to find “cortical swelling without CE” if a radiologist is not familiar with the findings of oligodendroglial tumors, which may introduce a bias. Advanced image techniques such as SWI and texture analysis are becoming standard in tumor imaging (12,24). However, these techniques were not performed because of the retrospective nature of this study. In future studies, we need to review more patients with GBMO and to examine the findings of other modalities such as FDG-PET.

In conclusion, there is a significant difference in CE in MRI. Specifically, there is a significant difference in the findings of CE, which exhibit solid heterogeneous enhancement in GBMO instead of ring-like enhancement, compared with the findings of cGBM. In particular, cortical swelling without CE is significantly characteristic of GBMO. The finding of solid heterogeneous enhancement and cortical swelling without CE may indicate the existence of oligodendroglioma foci in the GBM.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received the following financial support for the research, authorship, and/or publication of this article: This work was supported by a Grant-in-Aid from the Global COE program of the Japan Society for the Promotion of Science.

References
1. Perry A, Louis DN, Scheithauer BW, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, et al (eds) WHO Classification of Tumors of the Central Nervous System, 4th edn. Lyon: IARC, 2007, pp.33–49.
2. Kocaeli H, Yakut T, Bekar A, et al. Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report. Surg Neurol 2006;66:627–630.
3. Kanoto M, Toyoguchi Y, Hosoya T, et al. Delineation of malignant glioma by turbo spin echo multislice motion-sensitized driven-equilibrium (TSE-MSDE) with gadolinium-based contrast media: a case report. Magn Reson Imaging 2013;31:1251–1253.
4. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892–6899.
5. Wang Y, Li S, Chen L, et al. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol 2012;14:518–525.
6. Salvati M, Formichella AI, D’Elia A, et al. Cerebral glioblastoma with oligodendrogliomai component: analysis of 36 cases. J Neurooncol 2009;94:129–134.
7. Fellah S, Caudal D, De Paula AM, et al. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Am J Neuroradiol 2013;34:1326–1333.
8. Ha SY, Kang SY, Do IG, et al. Glioblastoma with oligodendrogliomal component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age. J Neurooncol 2013;112:439–448.
9. Laxton RC, Popov S, Doey L, et al. Primary glioblastoma with oligodendrogliomal differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro Oncol 2013;15:1635–1643.
10. Jiang H, Ren X, Wang J, et al. Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution. J Neurooncol 2014;116:395–404.
11. Louis DN, Suva ML, Burger PC, et al. Glioblastoma, IDH-wildtype. In: Louis DN, Ohgaki H, Wiestler OD, et al (eds) WHO Classification of Tumors of the Central Nervous System, (revised 4th edn). Lyon: IARC, 2016, pp.28–51.
12. Deistung A, Schweser F, Wiestler B, et al. Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PLoS One 2013;8:e57924.
13. Van den Bent MJ, Reni M, et al. Oligodendroglia. Crit Rev Oncol Hematol 2008;66:262–272.
14. Perry A, Louis DN, Scheithauer BW, et al. Oligodendroglia. In: Louis DN, Ohgaki H, Wiestler OD, et al (eds) WHO Classification of Tumors of the Central Nervous System, (4th edn). Lyon: IARC, 2007, pp.54–59.
15. Lee YY, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. Am J Roentgenol 1989;152:361–369.
16. Lee C, Duncan VW, Young AB. Magnetic resonance features of the enigmatic oligodendroglioma. Invest Radiol 1998;33:222–231.
17. Sunwoo L, Choi SH, Yoo RE, et al. Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. Neuroradiology 2015;57:1111–1120.
18. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002;58:111–117.
19. Fuji O, Soejima T, Kuwatsuka Y, et al. Supratentorial glioblastoma treated with radiotherapy: use of the Radiation Therapy Oncology Group recursive partitioning analysis grouping for predicting survival. Jpn J Clin Oncol 2010;40:726–731.
20. Klink B, Schlingelhof B, Klink M, et al. Glioblastomas with oligodendroglial component: common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst) 2010;33:37–54.
21. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108:49–56.
22. Goda JS, Lewis S, Agarwal A, et al. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma? Clin Neurol Neurosurg 2015;135:46–53.
23. Tortosa A, Viñolas N, Villà S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003;97:1063–1071.
24. Skogen K, Schulz A, Dormagen JB, et al. Diagnostic performance of texture analysis on MRI in grading cerebral gliomas. Eur J Radiol 2016;85:824–829.